6 assets in Anus Basaloid Carcinoma

Therapeutic assets addressing Anus Basaloid Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Carboplatin Anus Basaloid Carcinoma	National Cancer Institute (NCI)	P3	BB (66)
Nivolumab Anus Basaloid Carcinoma	National Cancer Institute (NCI)	P3	B (60)
Capecitabine Anus Basaloid Carcinoma	ECOG-ACRIN Cancer Research Group	P2	CCC (53)
Fludeoxyglucose Anus Basaloid Carcinoma	ECOG-ACRIN Cancer Research Group	P2	CCC (53)
Fluorouracilum Anus Basaloid Carcinoma	ECOG-ACRIN Cancer Research Group	P2	CCC (53)
Muamycin Anus Basaloid Carcinoma	ECOG-ACRIN Cancer Research Group	P2	CCC (53)